Why Response Varies — The Foundation
A structured treatment protocol applied to a heterogeneous condition will produce a range of responses. This is not a flaw in the protocol — it is an accurate reflection of how significantly HS patients differ from one another in the biological state they present with when treatment begins. Two patients who appear to have similar HS — both with axillary involvement, both Hurley Stage II, both in their mid-thirties — may have substantially different underlying metabolic states, gut microbiome compositions, hormonal profiles, degrees of immune dysregulation, and histories of prior treatment that collectively determine how readily their systems respond to correction.
The EPOH Protocol addresses the root-cause drivers of HS through a phased approach: reducing inflammatory load, restoring internal regulatory function, correcting hormonal and metabolic imbalance, and building the systemic resilience that prevents recurrence. Each of these phases depends on the patient's biological capacity to respond to correction — and that capacity varies considerably based on how long the disease has been active, what has been done to manage it in the interim, and what underlying systemic conditions are co-present.
Understanding these response determinants is not about creating categories of patients who will or will not benefit. It is about understanding the timeline and sequencing that different patient profiles require — and communicating this accurately from the outset rather than setting uniform expectations that will not hold across the full range of patient presentations.
"When a condition keeps recurring, it usually follows an underlying pattern that needs to be understood and addressed — not suppressed."
Profiles That Respond Earlier
Certain patient profiles consistently demonstrate earlier and more pronounced initial response to the EPOH Protocol. Identifying these features is not about preferring certain patients — it is about understanding what biological conditions allow for faster correction of the internal environment driving HS.
Shorter Disease Duration
Patients whose HS has been active for fewer than three to four years present with a biological environment that has been altered by inflammatory disease for a shorter period. Their immune regulatory capacity is less depleted. Their gut microbiome disruption — while present — has had less time to become entrenched. Their metabolic dysregulation is more recent and therefore more reversible. Their tissue environment has undergone less fibrotic change, and their systemic inflammatory load, while elevated, has not been sustained long enough to produce the metabolic memory and structural alterations seen in long-standing disease.
For these patients, the internal correction phase of treatment produces more rapid results because the systems being corrected have not been maintained in dysfunction long enough to require structural rebuilding rather than functional rebalancing. Flare frequency typically reduces noticeably within the first two to three months, and the transition toward a stable baseline is proportionally faster.
Limited Prior Systemic Treatment
Patients who have had minimal prior antibiotic use and no prolonged corticosteroid exposure present with a gut microbiome that, while disrupted by HS-associated factors, has not been additionally altered by repeated antibiotic courses. Their immune system has not been subject to prolonged suppression, and their baseline gut-immune axis function — while impaired — is closer to correctable normal than in patients with extensive prior treatment histories.
Repeated antibiotic courses in HS management produce collateral disruption to the gut microbiome that persists well beyond the treatment period. This disruption becomes an independent driver of systemic inflammation and immune dysregulation — separate from, and additional to, the disruption produced by HS itself. Patients without this additional layer of disruption are starting the correction process from a less compromised baseline.
Predominantly Inflammatory Rather Than Fibrotic Disease
Patients whose disease is characterised primarily by active inflammation — painful, fluctuant nodules and abscesses — rather than established fibrosis and sinus tract formation are responding to an active inflammatory process that can be modulated. The tissue environment, while inflamed, has not yet undergone the structural remodelling associated with chronic fibrosis, and the follicular structures in affected areas retain more normal architecture.
In contrast, patients with extensive sinus tract formation and established fibrosis have tissue that has been structurally remodelled by years of inflammation. This remodelling is not reversible in the same sense as reducing active inflammation — it changes the mechanical and biological environment of affected areas in ways that require a different treatment phase and a longer timeline for stabilisation.
In Ayurvedic clinical reasoning, the distinction between active inflammatory disease and established fibrotic change maps to the distinction between Ama-driven pathology — where accumulated inflammatory load is the primary driver — and Dhatu Kshaya, where tissue depletion and structural degradation have occurred. Ama-driven cases respond more rapidly to the cleansing and anti-inflammatory phases of treatment. Cases with significant Dhatu Kshaya require the additional rebuilding phases — the Rasayana approach that restores tissue integrity — before stabilisation can occur. These are fundamentally different therapeutic objectives that require different timeframes, and recognising this distinction at the outset allows for more accurate staging of treatment.
Profiles That Require Extended Timelines
Other patient profiles consistently require longer treatment timelines and more carefully sequenced phase progression. Extended timeline does not mean treatment ineffectiveness — it means that the degree of systemic correction required is greater, and that the biological capacity for rapid change is more limited at the outset.
Long Disease Duration with Extensive Systemic Involvement
Patients who have had HS for seven, ten, or more years present with a biological environment that has been maintained in chronic inflammatory dysregulation for an extended period. As described in the context of immune exhaustion, the regulatory capacity of their immune system has been progressively depleted. Their metabolic state reflects years of chronic inflammatory signalling — insulin sensitivity is reduced, cortisol regulation is often disrupted, and the hormonal environment has been modified by years of sustained inflammatory pressure. Their gut microbiome has been shaped by years of antibiotic use, dietary disruption associated with HS management, and the direct effects of systemic inflammation on gut barrier function.
Correcting these systems takes longer not because the protocol is less effective for these patients, but because the degree of correction required is substantially greater. Each phase of treatment is working against a more entrenched baseline, and the biological systems being restored have been functioning in a dysregulated state for long enough that restoration requires structural rebuilding rather than functional rebalancing.
Significant Metabolic Co-Morbidity
Patients with established insulin resistance, metabolic syndrome, or significant obesity present with a metabolic environment that actively sustains HS pathology through multiple mechanisms — elevated androgen production, heightened systemic inflammatory signalling, impaired adipose tissue immune function, and disrupted hormonal regulation. These metabolic factors are not independent of HS — they are bidirectionally linked, with each worsening the other — but they represent an additional layer of systemic correction that must be addressed alongside the direct HS drivers.
For these patients, the metabolic correction phase of treatment is both essential and time-intensive. Improving insulin sensitivity, reducing adipose-derived inflammation, and stabilising hormonal dysregulation cannot be achieved quickly. Progress in HS stabilisation is proportional to progress in metabolic correction, which means that patients with significant metabolic co-morbidity should expect a longer overall treatment timeline — not because their HS is being treated differently, but because the systemic environment that must be corrected before HS can stabilise is more extensively disrupted.
Extensive Prior Biologic Treatment
Patients who have undergone extended biologic therapy present a specific challenge. Biologics produce meaningful short-term reduction in inflammatory activity, and for many patients they provide significant relief during the period of treatment. However, the immune system that has been maintained in a suppressed state by biologic therapy has not been self-regulating during that period — it has been externally managed. When biologic treatment is withdrawn, or when the patient transitions to a root-cause approach, the immune system is returning to activity from a suppressed baseline rather than from a regulated one.
The transition period for these patients requires careful management. The initial phase of the protocol must account for the altered immune state that biologic exposure produces, and the timeline for re-establishing normal immune regulatory function from a suppressed baseline is longer than from a dysregulated but active one. This is not a contraindication to the EPOH Protocol — it is a sequencing and pacing consideration that must be factored into treatment planning.
"If it keeps coming back, it means the root cause has not been addressed."
What Determines the Pace of Response Within Each Profile
Within any patient profile, several factors modulate the pace of response in ways that are observable during treatment and can be used to adjust the sequencing and intensity of each phase.
Gut Restoration Capacity
The speed and completeness of gut microbiome restoration is one of the strongest determinants of overall treatment pace. The gut-immune axis is central to HS pathology — disrupted gut barrier function and altered microbial composition sustain the systemic inflammatory signalling that drives HS activity. Patients whose gut microbiome responds more readily to restoration — showing reduced inflammatory markers and improved digestive function within the early months of treatment — tend to show faster overall HS stabilisation, because the most significant source of ongoing systemic inflammatory drive is being addressed more quickly.
Patients with more entrenched gut dysbiosis — characterised by severely disrupted microbial diversity, persistent gut barrier dysfunction, or significant history of repeated antibiotic courses — require a more extended gut restoration phase before systemic inflammatory levels begin to drop meaningfully. Attempting to accelerate this phase produces diminishing returns; the pace of gut restoration is partly determined by the biology of microbial re-establishment and cannot be compressed beyond certain limits.
Hormonal Correction Trajectory
In patients with significant hormonal involvement — particularly women with PCOS-associated HS or patients with prominent androgen excess — the pace of hormonal correction substantially influences overall treatment trajectory. Hormonal systems are slower to correct than acute inflammatory activity, because hormonal regulation depends on the integrated function of multiple glands and feedback systems that have been disrupted over extended periods. Patients whose hormonal environment begins to normalise within the first three to four months of treatment tend to show more consistent HS stabilisation during the middle phases of the protocol.
Patients with more entrenched hormonal disruption — significant insulin resistance, adrenal dysregulation, or prolonged androgen excess — require more extended hormonal correction before HS activity fully reflects the correction. The protocol addresses hormonal correction as a dedicated phase, but the timeline for that correction is partly determined by the severity of prior disruption and cannot be accelerated beyond the pace at which the endocrine system is capable of rebalancing.
Lifestyle Alignment
The degree to which a patient can align with the dietary, sleep, and stress management components of the protocol substantially influences response pace. These components are not peripheral — they are integral to the protocol's effectiveness because they directly affect the internal inflammatory environment that treatment is trying to correct. Patients who are able to make meaningful dietary changes, establish consistent sleep patterns, and reduce chronic stress load create a biological environment that is more responsive to treatment. Patients who, for legitimate reasons, are unable to make these changes during the treatment period are working against a continued source of inflammatory drive that partially offsets the correction being achieved through treatment.
This is not a judgment — it is a practical reality about how internal inflammatory environments are maintained and how they respond to correction. It is one reason why the lifestyle component of the EPOH Protocol receives structured attention rather than being treated as optional advice.
What "Not Responding" Actually Means
In the context of the EPOH Protocol, apparent non-response in the early months should be interpreted carefully before concluding that the approach is not working. Root-cause treatment produces internal correction that precedes visible external change. The sequence is: internal inflammatory load reduces → regulatory function improves → hormonal environment stabilises → skin activity reflects these changes. This sequence takes time, and the external manifestation of improvement lags behind the internal correction that is producing it.
Patients who report no change in lesion activity in the first six to eight weeks of treatment have not been given sufficient time for the internal correction to manifest externally — provided the internal markers of correction (digestive improvement, reduction in systemic fatigue, stabilisation of hormonal symptoms) are showing early positive change. Absence of early external skin change is not absence of treatment effect; it is the expected sequence of a root-cause approach.
True non-response — absence of any internal or external change after a reasonable treatment period — requires clinical reassessment of the driving factors in that patient's case. In practice, this more commonly reflects an incomplete picture of the patient's underlying drivers at the outset rather than a failure of the protocol itself. Identifying a missed driver — an unrecognised source of gut disruption, an underappreciated hormonal component, an ongoing lifestyle factor sustaining inflammation — and adjusting the protocol accordingly is the clinical response to apparent non-response, not abandonment of the root-cause approach.
"The goal is not just to control symptoms, but to understand why the condition is occurring in the first place."
Setting Expectations That Are Accurate, Not Optimistic
The most important clinical function of understanding response variation is the ability to set expectations that are accurate rather than optimistic. Patients who are given an optimistic timeline that does not reflect their actual disease profile will experience apparent failure at the point where the optimistic timeline expires — not because treatment is failing, but because the timeline was not calibrated to their case.
Patients with shorter disease duration, limited prior treatment, and predominantly inflammatory disease can reasonably expect meaningful stabilisation within three to six months. Patients with long-standing disease, significant metabolic co-morbidity, extensive prior treatment, or established fibrosis should be counselled on timelines of nine to eighteen months or longer for meaningful stabilisation — with the understanding that the trajectory within that period will show progressive, if sometimes gradual, improvement rather than linear rapid change.
Accurate expectation-setting is itself a clinical intervention. Patients who understand their timeline are better positioned to persist through the phases of treatment where progress is internal rather than externally visible — which is often the phase where patients with unrealistic expectations discontinue treatment and conclude that the approach has not worked. The approach has worked; the timeline was simply not accurately communicated.